Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit

Journal of Hospital Infection

Volumn 59, Issue 2, 2005, Pages 83-89

  Aubert, Gerald ^a   Carricajo, A ^a   Vautrin, A C ^a   Guyomarc'h, S ^a   Fonsale, N ^a   Page, D ^a   Brunel, P ^a   Rusch, P ^a   Zeni F ^a  

^a SERVICE DE NEUROLOGIE   (France)

Author keywords

Antibiotic; Cycling; Fluoroquinolone; ICU; P. aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG USE; GRAM NEGATIVE INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; NONHUMAN; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; SCREENING TEST; VENTILATOR ASSOCIATED PNEUMONIA;

BACTERIAL INFECTIONS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FEMALE; FLUOROQUINOLONES; FRANCE; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, ASPIRATION; PSEUDOMONAS AERUGINOSA;

EID: 11244328852     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2004.07.016     Document Type: Article

References (19)

1. National Nosocomial Infection Surveillance (NNIS) System Report Data summary from January 1992 to June 2001 Am J Infect Control 29 2001 404-421
2. J.L. Trouillet A. Vuagnat A. Combes et al. Pseudomonas aeruginosa ventilator-associated pneumonia: Comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms Clin Infect Dis 34 2002 1047-1053
3. G.S. Guven O. Uzun Principles of good use of antibiotics in hospitals J Hosp Infect 53 2003 91-96
4. Aubert G, Vautrin AC, Pain P, Michel VP, Zeni F, Rush P. The therapeutic interest of restricting prescription of fluoroquinolones in an intensive care unit [Abstract E140]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 1995, San Francisco. Washington, DC: American Society for Microbiology; 1995 p. 110.
5. Anonymous. ATC classification index with DDDs Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2001.
6. G. Aubert B. Pozzetto G. Dorche Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy J Antimicrobiol Chemother 29 1992 307-312
7. M.M. Neuhauser R.A. Weinstein R. Rydman L.H. Danziger G. Karam J.P. Quinn Antibiotic resistance among Gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use JAMA 7 2003 885-888
8. D.M. Shlaes D.N. Gerding J.F. John et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals Infect Control Hosp Epidemiol 18 1997 275-291
9. J.E. McGowan Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control 7 1986 573-576
10. D.N. Gerding T.A. Larson R.A. Hugues M. Weiler C. Shanholtzer L.R. Peterson Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital Antimicrob Agents Chemother 35 1991 1284-1290
11. J.W. King M.C. White J.R. Todd S.A. Conrad Alterations in the microbial flora and in incidence of bacteremia at a university hospital after adoption of amikacine as the sole formulary aminoglycoside Clin Infect Dis 14 1992 908-915
12. J.J. Rahal C. Urban D. Hon et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA 280 1998 1233-1237
13. D. Gruson G. Hilbert F. Vargas et al. Rotation and restricted use of antibiotics in a medical intensive unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram negative bacteria Am J Respir Crit Care Med 162 2000 837-843
14. L.R. Peterson M. Postelnick T.L. Pozdol B. Reisberg G.A. Noskin Management of fluoroquinolone resistance in Pseudomonas aeruginosa-outcome of monitored use in a referral hospital Int J Antimicrob Agents 10 1998 207-214
15. R.P. Rifenburg J.A. Paladino S.M. Bhavnani D.D. Haese J.J. Schentag Influence of fluoroquinolone purchasing pattern on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility Am J Health Syst Pharm 56 1999 2217-2223
16. K. Drlica F.J. Schmitz Therapeutic options in an era of decreasing antimicrobial susceptibility Chemotherapy 14 2002 5-12
17. W.M. Sheld Maintaining fluoroquinolone class efficacy: Review of influencing factors Emerg Infect Dis 9 2003 1-9
18. E.M. Graffunder R.A. Venezia Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous antimicrobials J Antimicrob Chemother 49 2002 999-1005
19. S. Hori R. Sunley A. Tami H. Grundmann The Nottingham Staphylococcus aureus population study: Prevalence of MRSA among the elderly in a university hospital J Hosp Infect 50 2002 25-29